Telix Pharmaceuticals (TLX) Accumulated Expenses (2023 - 2024)
Telix Pharmaceuticals (TLX) posted Accumulated Expenses of $31.2 million for Q4 2024, up 26.58% on a QoQ basis from $24.7 million in Q4 2023, and up 26.58% year-over-year from $24.7 million in Q1 2024.
Telix Pharmaceuticals (TLX) has 2 years of Accumulated Expenses data on file, last reported at $31.2 million in Q4 2024.
- In Q4 2024, Accumulated Expenses rose 26.58% year-over-year to $31.2 million; the TTM figure through Dec 2024 stood at $31.2 million (up 26.58% YoY), while the FY2024 annual figure was $31.2 million, up 26.58% from the prior year.
- Accumulated Expenses advanced to $31.2 million in Q4 2024, from $24.7 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $31.2 million in Q4 2024 and bottomed at $24.7 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Telix Pharmaceuticals | 4.52 Bn | 4.38 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 31.23 Mn |
| Dec 31, 2023 | 24.67 Mn |